Molecular diagnostics

Research

Studying how circulating tumour cells and tumour-derived DNA can reveal treatment response and resistance in ovarian cancer.

Current focus

Liquid biopsy in HGSOC

My doctoral work combines longitudinal ctDNA profiling, functional CTC phenotyping and evidence synthesis to investigate tumour evolution during PARP inhibitor maintenance therapy.

ctDNA CTCs HGSOC PARP inhibitors Tumour evolution

Interactive study

Following tumour evolution in blood

Can liquid biopsy reveal emerging treatment resistance before clinical relapse?

Dynamic circulating tumour cell phenotypes and ctDNA evolution during PARP inhibitor therapy in HGSOC

To longitudinally characterise functional CTC phenotypes and ctDNA molecular evolution during PARPi maintenance therapy.

ESMO 2026 · Madrid, SpainISLB 2026 · Madrid, Spain · 7–9 November 2026
Explore the study

Evidence synthesis

From published evidence to new experiments

A PROSPERO-registered systematic review and meta-analysis maps the evidence for circulating biomarkers in high-grade serous ovarian cancer.

Ongoing project

Liquid Biopsy Biomarkers in HGSOC

Systematic review and meta-analysis following a complete PRISMA workflow.

View project